Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: The ESPORT study

Journal of Hypertension

Volumn 28, Issue 11, 2010, Pages 2342-2350

  Malacco, Ettore ^a   Omboni, Stefano ^b   Volpe, Massimo ^c   Auteri, Alberto ^d   Zanchetti, Alberto ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

ambulatory blood pressure monitoring; elderly; essential hypertension; office blood pressure; olmesartan; ramipril

Indexed keywords

OLMESARTAN; PLACEBO; RAMIPRIL;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EPIGASTRIC PAIN; ERYTHEMA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER;

EID: 77958463672     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833e116b     Document Type: Article

References (42)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burdenofhypertension: analysisofworldwide data.Lancet 2005; 365:217-223.
2. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-1354.
3. Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986; 293:1145-1151.
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255-3264.
5. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
6. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304:405-412.
7. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
8. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, etal. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
9. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated sistoli hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160:211-220.
10. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
11. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466-472.
12. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55:1056-1065.
13. Chobanian AV. Shattuck Lecture. The hypertension paradox: more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361:878-887.
14. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1498.
15. Acelajado MC, Oparil S. Hypertension in the elderly. Clin Geriatr Med 2009; 25:391-412.
16. Rashidi A, Wright JT Jr. Drug treatment of hypertension in older hypertensives. Clin Geriatr Med 2009; 25:235-244.
17. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121-1123.
18. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
19. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
20. Prisant LM. Now or never: optimal antihypertensive therapy in the elderly. Prev Cardiol 2008; 11:201-209.
21. Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P, Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004; 26:855-865. (Pubitemid 38943034)
22. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23:610-619.
23. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17:911-923.
24. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6:161-166.
25. Lacourcière Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged or65 years with mild to moderate hypertension. Clin Ther 2000; 22:1213-1224.
26. Ruilope L, Jäger B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001; 10:223-229.
27. Destro M, Preti P, D'Ospina A, Christian Achiri NN, Ricci AR, Cagnoni F. Olmesartan medoxomil: recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol 2009; 5:1149-1157.
28. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68:1239-1272.
29. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26:61-76.
30. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25:2168-2177.
31. O'Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, et al. Working group on blood pressure monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit 2002; 7:3-17.
32. Parati G, Omboni S, Palatini P, Rizzoni D, Bilo G, Valentini M, et al. Italian Society of Hypertension Guidelines for Conventional and Automated Blood Pressure Measurement in the Office, at Home and Over 24 Hours. High Blood Press Cardiovasc Prev 2008; 15:283-310.
33. Rizzoni D, Castellano M, Muiesan ML, Porteri E, Agabiti-Rosei E. Beyond trough:peak ratio: a new index of the smoothness of the antihypertensive effect of a drug. High Blood Press 1997; 6:110-115.
34. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G.The smoothness index: a new, reproducible and officially relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16:1685-1691.
35. Omboni S, Parati G, Mancia G. The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension. Blood Pressure Monit 1998; 3:201-204.
36. Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P, Val-Syst study. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003; 25:2765-2780.
37. Volpe M, Junren Z, Maxwell T, Rodriguez A, Gamboa R, Gomez-Fernandez P, et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan-and Amlodipine-based regimens in patients with isolated sistoli hypertension. Clin Ther 2003; 25:1469-1489.
38. Neldam S, Edwards C, ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15:151-160.
39. Neldam S, Forsén B, Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001; 18:225-232.
40. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25:1327-1336.
41. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23:2083-2092.
42. Smith DH, Dubiel R, Jones M. Use of 24-h ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5:41-50.